39757-71-6

Usage

Uses

Used in Pharmaceutical Synthesis:
4-(4-Trifluoromethyl-Phenyl)-Piperidin-4-ol is used as a key intermediate in the synthesis of trifluperidol (CAS number T793533), a potent antipsychotic drug. Its role in the production of trifluperidol is significant, as it contributes to the drug's efficacy in treating various psychiatric disorders, including schizophrenia and other psychotic conditions.
Used in the Chemical Industry:
In addition to its pharmaceutical applications, 4-(4-Trifluoromethyl-Phenyl)-Piperidin-4-ol may also be utilized in the chemical industry for the development of other related compounds with potential applications in various fields, such as agrochemicals, materials science, and more. Its unique structure and properties make it a valuable building block for the synthesis of novel molecules with diverse functionalities.

Upstream product

• 1191240-41-1 tert-butyl 4-hydroxy-4-(4-(trifluoromethyl)phenyl)-1-piperidinecarboxylate 
• 4783-65-7 N-benzyl-2-piperidinone 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 137885-29-1 ethyl 4-hydroxy-4-[4-(trifluoromethyl)phenyl]piperidine-1-carboxylate 
• 58778-51-1 1-benzyl-4-(4-(trifluoromethyl)phenyl)-piperidin-4-ol 

Downstream Products

• 58778-52-2 1,2,3,6-tetrahydro-4-(α,α,α-trifluoro-p-tolyl)-pyridine hydrochloride 
• 58778-61-3 1-acetyl-3-{2-[4-hydroxy-4-(4-trifluoromethyl-phenyl)-piperidin-1-yl]-ethyl}-2,3-dihydro-indole 
• 35309-61-6 1-(4-fluorophenyl)-4-(4-hydroxy-4-(4-(trifluoromethyl)phenyl)piperidin-1-yl)butan-1-one 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

Structure-Kinetic Profiling of Haloperidol Analogues at the Human Dopamine D2 Receptor

Haloperidol is a typical antipsychotic drug (APD) associated with an increased risk of extrapyramidal side effects (EPSs) and hyperprolactinemia relative to atypical APDs such as clozapine. Both drugs are dopamine D2 receptor (D2R) antagonists, with contrasting kinetic profiles. Haloperidol displays fast association/slow dissociation at the D2R, whereas clozapine exhibits relatively slow association/fast dissociation. Recently, we have provided evidence that slow dissociation from the D2R predicts hyperprolactinemia, whereas fast association predicts EPS. Unfortunately, clozapine can cause severe side effects independent of its D2R action. Our results suggest an optimal kinetic profile for D2R antagonist APDs that avoids EPS. To begin exploring this hypothesis, we conducted a structure-kinetic relationship study of haloperidol and revealed that subtle structural modifications dramatically change binding kinetic rate constants, affording compounds with a clozapine-like kinetic profile. Thus, optimization of these kinetic parameters may allow development of novel APDs based on the haloperidol scaffold with improved side-effect profiles.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.

DIPHENYLBUTYPIPERIDINE AUTOPHAGY INDUCERS

Autophagy inducing compounds, methods of their preparation and use, and kits containg said compounds are disclosed herein.

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

The invention relates to substituted 1-piperazinylacylpiperidine derivatives of general formula (I) in which: n is 1 or 2; p is 1 or 2; R1 represents a halogen atom; a trifluoromethyl radical; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethoxy radical; R2 represents a hydrogen atom or a halogen atom; R3 represents a hydrogen atom; a group —OR5; a group —CH2OR5; a group —NR6R7; a group —NR8COR9; a group —NR8CONR10R11; a group —CH2NR12R13; a group —CH2NR8CONR14R15; a (C1-C4)alkoxycarbonyl; a group —CONR16R17; or else R3 constitutes a double bond between the carbon atom to which it is attached and the adjacent carbon atom of the piperidine ring; R4 represents an aromatic group selected from: the said aromatic groups being unsubstituted or being mono- or disubstituted by a substituent selected independently from a halogen atom; a (C1-C4)alkyl; a (C1-C4)alkoxy; a trifluoromethyl radical; Preparation process and therapeutic application.

INDOLE DERIVATIVE AND USE FOR TREATMENT OF CANCER

The present invention relates to a compound represented by the formula (I’) wherein A is a benzene ring optionally having substituents, R1, R2a and R3 are each a hydrogen atom, a hydrocarbon group optionally having substituents or a heterocyclic group optionally having substituents, R1 and R2a may form a ring via X, when R1 and R2a form a ring via X, R1 and R2a are each a bond or a divalent C1-5 acyclic hydrocarbon group optionally having substituents, and X is a bond, an oxygen atom, an optionally oxidized sulfur atom or an imino group optionally having a substituent, provided that R1, R2a and X are not bonds at the same time, or a salt thereof, and an agent for inhibiting kinase (phosphorylation enzyme), which contains this compound or a prodrug thereof. The compound of the present invention has an inhibitory activity against kinase such as a vascular endothelial growth factor receptor (VEGFR) and the like, and is useful as an agent for the prophylaxis or threatment of cancer and the like.

Dipeptides which promote release of growth hormone

Compounds of formula (I) are growth hormone releasing peptide mimetics which are useful for the treatment and prevention of osteoporosis. STR1

Neuroprotective 3,4-dihydro-2(1H)-quinolone compounds

The present invention is directed to compounds of formula (I), and the pharmaceutically acceptable acid addition salts thereof, wherein R is selected from the group consisting of F,--CF3, --OCH3, --O(C1)alkyl substituted with 1 to 3 fluoro atoms. --O(C2) substituted with 1 to 5 fluoro atoms, and --O(C3)alkyl substituted with 1 to 7 fluoro atoms. The compounds of formula (I) are useful in the treatment of stroke, traumatic brain injury and central nervous system degenerative diseases.

1-Acyl-3-[2-(4-phenyl-1-piperidinyl)ethyl]indolines

This disclosure describes new substituted 1-acyl-3-[2-(4-phenyl-1-piperidinyl)ethyl]indolines which possess hypotensive activity.